Mantle cell lymphoma: Report of the 2009 mantle cell lymphoma consortium workshop

Leukemia and Lymphoma

Volumn 51, Issue 3, 2010, Pages 390-398

  Williams, Michael E ^a   Dreyling, Martin H ^b   Kahl, Brad S ^c   Leonard, John P ^d   O'Connor, Owen A ^e   Press, Oliver W ^f   Wilson, Wyndham H ^g  

^a UNIVERSITY OF VIRGINIA   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f USA   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive cellular therapy; Antibody based immunotherapy; Cell cycle and apoptosis; Mantle cell lymphoma; Minimal residual disease (MRD)

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BORTEZOMIB; CANFOSFAMIDE; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARTHENOLIDE; PREDNISOLONE; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG INDUCED HEADACHE; FATIGUE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IMMUNOTHERAPY; MANTLE CELL LYMPHOMA; NEUTROPENIA; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; AGED; BIOLOGICAL THERAPY; GENETICS; LYMPHOMA, MANTLE-CELL; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PROCEDURES; RISK; TREATMENT OUTCOME;

AGED; APOPTOSIS; CELL CYCLE; CELL- AND TISSUE-BASED THERAPY; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; MEDICAL ONCOLOGY; MIDDLE AGED; RISK; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77249122491     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903503453     Document Type: Article

References (26)

1. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838.
2. Zhang J, Jima DD, Jacobs C, et al. Patterns of microRNA expression characterize stages of human B cell differentiation. Blood 2009;113:4586-4594.
3. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833.
4. Liu H, Wang J, Epner EM. Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. Blood 2004;104:2505-2513.
5. Liu H, Huang J, Wang J, et al. Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma. J Exp Med 2008;205:1843-1858.
6. Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006;441:106-110.
7. Habermann TM, Maurer MJ, Wang SS, et al. Host genetic variation in the cell cycle and NF-kB pathways and overall survival in mantle cell lymphoma. Presented at the 49th American Society of Hematology Annual Meeting and Exposition, December 8-11, 2007, Atlanta, Georgia. (Abstract 1582).
8. Marzec M, Kasprzycka M, Lai R, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006;108:1744-1750.
9. Hsi ED, Jung SH, Lai R, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008;49:2081-2090.
10. Schrage MI, Kim D, Calimlim J, et al. The PIM1 oncogene accelerates TCL1 driven lymphomagenesis in a double-transgenic murine model. Presented at the 50th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2008, San Francisco, California. (Abstract 1806).
11. Wang Q, Mora-Jensen H, Weniger MA, et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA 2009;106:2200-2205.
12. Fiebiger E, Hirsch C, Vyas JM, Gordon E, Ploegh HL, Tortorella D. Dissection of the dislocation pathway for type I membrane proteins with a new small molecule inhibitor, eeyarestatin. Mol Biol Cell 2004;15:1635-1646.
13. Wang Q, Li L, Ye Y. Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem 2008;283:7445-7454.
14. Hoster E, Unterhalt M, Wörmann B, et al. The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial. Presented at the 50th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2008, San Francisco, California. (Abstract 3049).
15. Dreyling MH, Hoster E, Van Hoof A, et al. Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma: long term follow up of a randomized trial of the [European MCL Network]. Presented at the 50th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2008, San Francisco, California. (Abstract 769).
16. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
17. Pott C, Hoster E, Böttcher S, et al. Molecular remission after combined immunochemotherapy is of prognostic relevance in patients with MCL: results of the randomized intergroup trials of the European MCL Network. Presented at the 50th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2008, San Francisco, California. (Abstract 582).
18. Hutter G, Zimmermann Y, Weinkauf M, et al. The functional impact of PKCß/PI3K/AKT signalling on translational initiation in MCL. Presented at the 50th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2008, San Francisco, California. (Abstract 2624).
19. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008;112:830-835.
20. Kiziltepe T, Hideshima T, Catley L, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007;6:1718-1727.
21. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
22. Gupta M, Ansell SM, Novak AJ, Witzig TE. Histone deacetylase inhibition with LBH589 inhibits the rapamycin insensitive Rictor-mTOR (mTORC2) complex and translation initiation factor eIF4E activation in diffuse large b-cell lymphoma. Presented at the 50th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2008, San Francisco, California. (Abstract 603).
23. Bennaceur-Griscelli A, Bosq J, Koscielny S, et al. High level of glutathione-S-transferase p expression in mantle cell lymphomas. Clin Cancer Res 2004;10:3029-3034.
24. Schumaker L, Nikitakis N, Goloubeva O, Tan M, Taylor R, Cullen KJ. Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin Cancer Res 2008;14:5877-5883.
25. Voso MT, Hohaus S, Guidi F, et al. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 2008;22:1685-1691.
26. Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008;7:3247-3255.